Hoth Therapeutics Utilizes Lantern Pharma's PredictBBB.ai Platform — Innovative AI Achieving 94% Accuracy to Propel Next-Generation Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Source: Newsfilter
Hoth Therapeutics Adopts AI Technology: Hoth Therapeutics, Inc. has announced the integration of Lantern Pharma's PredictBBB.ai™ platform, an AI tool with 94% accuracy in predicting blood-brain barrier permeability, to enhance its drug development process.
Impact on Drug Development: The adoption of this AI-driven solution is expected to streamline candidate selection, reduce development risks, and accelerate timelines for transformative therapies, aligning with Hoth's commitment to innovative and efficient drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOTH
About HOTH
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic program has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which strengthens the company's intellectual property foundation in the biopharmaceutical sector.
- Technological Innovation: The allowed antisense oligomers aim to reduce cell-surface expression of the high-affinity IgE receptor, providing a novel therapeutic mechanism distinct from traditional antihistamines and small-molecule inhibitors, potentially offering better efficacy in allergic and inflammatory diseases.
- Broad Indication Coverage: The allowed method claims span various diseases, including asthma, atopic dermatitis, and allergic conjunctivitis, indicating the HT-KIT program's extensive potential in treating mast cell-driven diseases, which may open new market opportunities for the company.
- Strategic Restructuring Plan: Hoth is exploring placing its biotechnology pipeline and therapeutic development programs under a wholly owned subsidiary to better manage resources and protect shareholder value while continuing to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which is expected to enhance its market competitiveness in allergic and inflammatory diseases.
- Scientific Validation: CEO Robb Knie stated that this allowance serves as a significant validation of the science underlying their mast cell platform, further strengthening the intellectual property foundation of the HT-KIT program, which may drive future clinical research and product development.
- IND Submission Plans: Hoth expects to finalize its IND submission for the HT-KIT program in 2026, followed by first-in-human studies, which will lay the groundwork for innovative treatments in mast cell-driven diseases.
- Subsidiary Structure Adjustment: The company is exploring placing its biotechnology pipeline and therapeutic development projects under a separate wholly-owned subsidiary to preserve the value of its biotechnology portfolio while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure.
See More
Hoth Rebrands to Rocket One, Targets AI Semiconductor Market
- Strategic Restructuring: Hoth has announced its rebranding to Rocket One and is restructuring its business through a wholly-owned subsidiary to focus on artificial intelligence infrastructure and next-generation semiconductor technologies, aiming to capitalize on the rapidly growing AI market.
- Exclusive Technology Licensing: The company has secured exclusive rights to AI acceleration technology based on non-volatile nanomagnetic semiconductor architecture and spintronic computing technologies, which are expected to significantly enhance energy efficiency and computing performance, addressing current power consumption challenges in AI infrastructure.
- Market Potential: As global demand for large language models and generative AI surges, Rocket One's technologies are poised to provide strong competitive advantages in the AI semiconductor market, potentially driving future revenue growth for the company.
- Biotechnology Continuation: The company plans to place its biotechnology assets into a separate subsidiary to preserve their value while allowing the parent company to focus on the rise of AI semiconductor infrastructure, demonstrating a forward-looking approach to future technological developments.
See More
Spain Approves Hoth's Clinical Trial for HT-001
- Regulatory Approval Progress: Hoth Therapeutics has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, laying the groundwork for the company's strategic expansion in Europe and expected acceleration of clinical trial execution.
- Positive Clinical Results: Preliminary data indicate that HT-001 shows significant efficacy in alleviating EGFR inhibitor-related skin toxicities, enabling patients to remain on life-saving cancer therapies longer, thus addressing a major limitation of current oncology treatment regimens.
- Market Potential Unveiled: Hoth's CEO Robb Knie stated that the combination of regulatory progress and strong clinical signals opens a new treatment avenue for patients in Spain, positioning HT-001 as a potential critical supportive care therapy in oncology.
- Innovative Treatment Goals: HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with cancer therapy-induced skin toxicities, aiming to improve patient tolerability and ensure uninterrupted treatment, thereby enhancing overall patient quality of life.
See More
Hoth Therapeutics Shares Surge 55% on Positive HT-VA Study Results
- Significant Study Results: Hoth Therapeutics' HT-VA study demonstrated that GDNF can directly reprogram liver fat metabolism at the genetic level in diet-induced obesity and metabolic-associated fatty liver disease, significantly decreasing Srebf1 expression while increasing Ppara expression, highlighting its crucial role in fat metabolism.
- Strong Market Performance: Following the announcement of the study results, HOTH shares surged over 55% in pre-market trading, rising by $0.80 to a 58.23% increase, reflecting strong market confidence and anticipation for the new therapy.
- Future Development Plans: Hoth plans to advance HT-VA findings into additional preclinical validation studies and evaluate clinical development pathways for metabolic and liver diseases, indicating the company's ongoing commitment and strategic positioning in new therapies.
- Diverse R&D Pipeline: In addition to HT-VA, Hoth is also developing HT-001, HT-KIT, and HT-ALZ targeting skin reactions in cancer patients, mast cell-driven disorders, and Alzheimer's disease, showcasing its broad portfolio and potential in the biopharmaceutical sector.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic program has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which strengthens the company's intellectual property foundation in the biopharmaceutical sector.
- Technological Innovation: The allowed antisense oligomers aim to reduce cell-surface expression of the high-affinity IgE receptor, providing a novel therapeutic mechanism distinct from traditional antihistamines and small-molecule inhibitors, potentially offering better efficacy in allergic and inflammatory diseases.
- Broad Indication Coverage: The allowed method claims span various diseases, including asthma, atopic dermatitis, and allergic conjunctivitis, indicating the HT-KIT program's extensive potential in treating mast cell-driven diseases, which may open new market opportunities for the company.
- Strategic Restructuring Plan: Hoth is exploring placing its biotechnology pipeline and therapeutic development programs under a wholly owned subsidiary to better manage resources and protect shareholder value while continuing to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which is expected to enhance its market competitiveness in allergic and inflammatory diseases.
- Scientific Validation: CEO Robb Knie stated that this allowance serves as a significant validation of the science underlying their mast cell platform, further strengthening the intellectual property foundation of the HT-KIT program, which may drive future clinical research and product development.
- IND Submission Plans: Hoth expects to finalize its IND submission for the HT-KIT program in 2026, followed by first-in-human studies, which will lay the groundwork for innovative treatments in mast cell-driven diseases.
- Subsidiary Structure Adjustment: The company is exploring placing its biotechnology pipeline and therapeutic development projects under a separate wholly-owned subsidiary to preserve the value of its biotechnology portfolio while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure.
See More
Hoth Rebrands to Rocket One, Targets AI Semiconductor Market
- Strategic Restructuring: Hoth has announced its rebranding to Rocket One and is restructuring its business through a wholly-owned subsidiary to focus on artificial intelligence infrastructure and next-generation semiconductor technologies, aiming to capitalize on the rapidly growing AI market.
- Exclusive Technology Licensing: The company has secured exclusive rights to AI acceleration technology based on non-volatile nanomagnetic semiconductor architecture and spintronic computing technologies, which are expected to significantly enhance energy efficiency and computing performance, addressing current power consumption challenges in AI infrastructure.
- Market Potential: As global demand for large language models and generative AI surges, Rocket One's technologies are poised to provide strong competitive advantages in the AI semiconductor market, potentially driving future revenue growth for the company.
- Biotechnology Continuation: The company plans to place its biotechnology assets into a separate subsidiary to preserve their value while allowing the parent company to focus on the rise of AI semiconductor infrastructure, demonstrating a forward-looking approach to future technological developments.
See More
Spain Approves Hoth's Clinical Trial for HT-001
- Regulatory Approval Progress: Hoth Therapeutics has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, laying the groundwork for the company's strategic expansion in Europe and expected acceleration of clinical trial execution.
- Positive Clinical Results: Preliminary data indicate that HT-001 shows significant efficacy in alleviating EGFR inhibitor-related skin toxicities, enabling patients to remain on life-saving cancer therapies longer, thus addressing a major limitation of current oncology treatment regimens.
- Market Potential Unveiled: Hoth's CEO Robb Knie stated that the combination of regulatory progress and strong clinical signals opens a new treatment avenue for patients in Spain, positioning HT-001 as a potential critical supportive care therapy in oncology.
- Innovative Treatment Goals: HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with cancer therapy-induced skin toxicities, aiming to improve patient tolerability and ensure uninterrupted treatment, thereby enhancing overall patient quality of life.
See More
Hoth Therapeutics Shares Surge 55% on Positive HT-VA Study Results
- Significant Study Results: Hoth Therapeutics' HT-VA study demonstrated that GDNF can directly reprogram liver fat metabolism at the genetic level in diet-induced obesity and metabolic-associated fatty liver disease, significantly decreasing Srebf1 expression while increasing Ppara expression, highlighting its crucial role in fat metabolism.
- Strong Market Performance: Following the announcement of the study results, HOTH shares surged over 55% in pre-market trading, rising by $0.80 to a 58.23% increase, reflecting strong market confidence and anticipation for the new therapy.
- Future Development Plans: Hoth plans to advance HT-VA findings into additional preclinical validation studies and evaluate clinical development pathways for metabolic and liver diseases, indicating the company's ongoing commitment and strategic positioning in new therapies.
- Diverse R&D Pipeline: In addition to HT-VA, Hoth is also developing HT-001, HT-KIT, and HT-ALZ targeting skin reactions in cancer patients, mast cell-driven disorders, and Alzheimer's disease, showcasing its broad portfolio and potential in the biopharmaceutical sector.
See More
REPL Faces Pressure After FDA Issues Second Complete Response Letter
- Regulatory Pressure on REPL: REPL's stock plummeted 64% after the FDA issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with nivolumab for anti-PD-1-failed melanoma, highlighting a lack of alignment with the FDA and prompting widespread analyst downgrades across Wall Street.
- HOTH Financing Impact: HOTH's stock declined 1% following the announcement of a $2 million stock offering priced at $0.70 per share, overshadowing positive pipeline updates for its HT-001 therapy, which showed significant efficacy in treating skin toxicities, indicating market concerns over dilution.
- ONCO's Stock Slide: ONCO's shares fell 27% after implementing a 1-for-5 reverse stock split to comply with Nasdaq's minimum bid price requirement, despite ongoing efforts to acquire Realbotix in an all-stock deal, reflecting investor anxiety over compliance pressures.
- Retail Investor Sentiment: Retail sentiment on Stocktwits showed REPL as 'bearish' while HOTH and ONCO were 'extremely bullish', indicating a divergence in market sentiment despite all three stocks underperforming the broader XLV ETF over the past year, with declines of 77%, 36%, and 97% respectively.
See More
